These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33852086)

  • 1. Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?
    Orrico M; Nozzolillo A; Gelibter S; Sangalli F; Preziosa P; Filippi M; Moiola L
    J Neurol; 2021 Nov; 268(11):3975-3979. PubMed ID: 33852086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
    Yagi Y; Nakamura Y; Kitahara K; Harada T; Kato K; Ninomiya T; Cao X; Ohara H; Izumi-Nakaseko H; Suzuki K; Ando K; Sugiyama A
    Toxicol Appl Pharmacol; 2014 Nov; 281(1):39-47. PubMed ID: 25223691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed high-grade atrioventricular block requiring pacemaker implantation in a multiple sclerosis patient treated with fingolimod.
    Feige J; Schernthaner C; Wipfler P; Sellner J
    Mult Scler Relat Disord; 2020 Feb; 38():101515. PubMed ID: 31751857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic.
    Brown B; Weiss JL; Kolodny S; Meng X; Williams IM; Osborne JA
    BMC Neurol; 2019 Nov; 19(1):287. PubMed ID: 31729968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
    Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
    Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 8. Mobitz type I and II atrioventricular blocks during fingolimod therapy.
    Saccà F; Puorro G; Marsili A; Pane C; Russo CV; Lanzillo R; de Rosa A; Cittadini A; De Angelis G; Brescia Morra V
    Neurol Sci; 2016 Sep; 37(9):1557-9. PubMed ID: 27225279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
    Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL;
    BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.
    Leo A; Citraro R; Marra R; Palma E; Paola EDD; Constanti A; De Sarro G; Russo E
    CNS Neurol Disord Drug Targets; 2017; 16(3):311-325. PubMed ID: 27823573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
    McGowan EM; Haddadi N; Nassif NT; Lin Y
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for the use of sphingosine analogues in COVID-19 patients.
    Tasat DR; Yakisich JS
    Clin Med (Lond); 2021 Jan; 21(1):e84-e87. PubMed ID: 33144402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed cardiac dysrhythmias after fingolimod administration.
    Rosini JM; Rajasimhan S; Fellows SE; Nomura JT
    Am J Emerg Med; 2015 Jul; 33(7):987.e1-3. PubMed ID: 25669873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue.
    Egom EE; Kruzliak P; Rotrekl V; Lei M
    J Cell Mol Med; 2015 Jul; 19(7):1729-34. PubMed ID: 25864579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
    Harada T; Wilbraham D; de La Borderie G; Inoue S; Bush J; Camm AJ
    Br J Clin Pharmacol; 2017 May; 83(5):1011-1027. PubMed ID: 27921320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
    Paolicelli D; Manni A; Direnzo V; D'Onghia M; Tortorella C; Zoccolella S; Trojano M
    J Clin Pharmacol; 2015 Oct; 55(10):1131-6. PubMed ID: 25903516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of Fingolimod on patients with moderate to severe COVID-19.
    Teymouri S; Pourbayram Kaleybar S; Hejazian SS; Hejazian SM; Ansarin K; Ardalan M; Zununi Vahed S
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01039. PubMed ID: 36567519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation and Optimization of
    Gusman DH; Shoemake C
    Yale J Biol Med; 2017 Mar; 90(1):15-23. PubMed ID: 28356890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.